Weather , , 0°C

Candidemia Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Candidemia Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

July 20
20:55 2021
Candidemia Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

DelveInsight Business Research LLP
DelveInsight’s “Candidemia Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Candidemia pipeline landscapes. It comprises Candidemia pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Candidemia therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Candidemia pipeline products.

DelveInsight’s “Candidemia Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Candidemia pipeline landscapes. It comprises Candidemia pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Candidemia therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Candidemia pipeline products.   

 

Some of the key takeaways of the Candidemia Pipeline Report  

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such asAmplyx Pharmaceuticals, Cidara Therapeutics, Scynexis, etc., are developing therapies for the treatment of Candidemia.

  • Emerging therapies such as APX001, CD101, SCY-078, are expected to have a significant impact on the  Candidemia market in the coming years.

  • The market Size of candidemia in the 7MM was found to be USD  2,263.1  million in 2017.

  • Among the 7MM, the US accounted for 49.6% of the overall market size of candidemia in 2017. 

Get an overview of pipeline landscape @ Candidemia Clinical Trials Analysis  

Candidemia is the most common fungal bloodstream infection and possibly the fourth most common all-type bloodstream infection seen in the intensive care unit setting. The incidence of Candida bloodstream infection is bimodal, with the elderly and very young having the highest risk of any population suffering from this disease.

Candidemia Emerging Drugs

  1. APX001 by Amplyx Pharmaceuticals

  2. CD101 by Cidara Therapeutics

  3. SCY-078 by Scynexis

  4. And others.

Scope of Candidemia Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players:Amplyx Pharmaceuticals, Cidara Therapeutics, Scynexis, and others.

  • Pipeline Therapies: APX001, CD101, SCY-078, and others.

Table of Contents

1

Candidemia Report Introduction

2

Candidemia Executive Summary

3

Candidemia Overview

4

Candidemia- Analytical Perspective In-depth Commercial Assessment

5

Candidemia Pipeline Therapeutics

6

Candidemia Late Stage Products (Phase II/III)

7

Candidemia Mid Stage Products (Phase II)

8

Candidemia Early Stage Products (Phase I)

9

Candidemia Preclinical Stage Products

10

Candidemia Therapeutics Assessment

11

Candidemia Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Candidemia Key Companies

14

Candidemia Key Products

15

Candidemia Unmet Needs

16 

Candidemia Market Drivers and Barriers

17

Candidemia Future Perspectives and Conclusion

18

Candidemia Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @ Candidemia Drugs Pipeline Report  

Related Reports:

Candidemia Market 

DelveInsight’s Candidemia – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Candidemia, historical and forecasted epidemiology as well as the Candidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Candidemia Epidemiology 

DelveInsight’s ‘ Candidemia- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted  Candidemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Calendar

August 2021
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

Categories